At present, allergic rhinitis has a targeted treatment method, but it is only applicable to some patients, and its efficacy may vary from person to person, the specific treatment should be carried out in accordance with the doctor’s instructions.
Targeted therapy refers to the method of reducing the dosage of drugs and accurately localizing to the lesion area by targeting some specific goals or parts in the treatment process. Currently, targeted drugs against IgE antibodies (e.g., omalizumab) have been used in the treatment of allergic rhinitis. Therefore, allergic rhinitis can be treated with targeted therapy.
However, it should be noted that targeted therapy is not the first choice of treatment for allergic rhinitis. It is only suitable for patients with severe disease who have not been treated with other drugs (e.g., glucocorticosteroids, antihistamines, etc.), and because of the long treatment period and high cost of these drugs, they have not been widely used in the clinic.
In addition, it should be noted that anti-IgE antibody targeted drugs are prohibited for people who are allergic to them, and headache, fever and other adverse reactions may occur during the use of the drug. The efficacy of these drugs may vary depending on the individual’s physical condition, timing and compliance with treatment, and other interventions.
In conclusion, those who have been diagnosed with allergic rhinitis must determine whether targeted therapy is appropriate under the guidance of a doctor and carry out standardized operations, and must not blindly use drugs or increase or decrease the amount of drugs on their own to avoid adverse consequences.